Precision BioSciences And iECURE Announce License And Collaboration Agreement To Develop ARCUS-Based Gene Editing Therapies

iECURE to License Precision’s PCSK9-Directed ARCUS Nuclease and Pursue Four Gene Insertion Programs Focused on Liver Diseases; Precision Retains Rights Across All Indications Except Those Licensed to iECURE

byBenzinga Newsdesk

September 9, 2021

1 minute read

iECURE Expects to File a Clinical Trial Application as Early as 2022 for Precision’s PBGENE-PCSK9 Candidate for Familial Hypercholesterolemia

Preclinical Data for ARCUS-Mediated Gene Insertion to be Presented Today by iECURE Chief Scientific Advisor, James M. Wilson, M.D., Ph.D. at Precision’s Gene Editing R&D Event

Betting The Ponies: DraftKings Launching New Offering For Customers

By Chris Katje

Today, 11:23 PM

Sports betting company DraftKings Inc (NASDAQ: DKNG) is launching a new offering to attract additional customers and potentially lower customer churn. Here are the details.

CHDN

RBC Capital Maintains Outperform on Chipotle Mexican Grill, Raises Price Target to $1800

By Benzinga Newsdesk

Today, 11:23 PM

RBC Capital analyst Christopher Carril maintains Chipotle Mexican Grill (NYSE:CMG) with a Outperform and raises the price target from $1750 to $1800.

CMG

Motorola Solutions Q4 Adj. EPS $3.60 Beats $3.43 Estimate, Sales $2.71B Beat $2.53B Estimate

By Michael Horton

Today, 11:23 PM

Motorola Solutions (NYSE:MSI) reported quarterly earnings of $3.60 per share which beat the analyst consensus estimate of $3.43 by 4.96 percent. This is a 26.32 percent increase over earnings of $2.85 per share from the

MSI